Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00706537 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT00706537: Completed Phase 1 study, sponsored by Pfizer.
NCT00706537 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00706537, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
CP-945598 is a potent and selective Cannabinoid-1 (CB1) receptor antagonist currently being developed for the treatment of obesity. CP-945598 is also being considered as a potential treatment for non-alcoholic steatohepatitis (NASH). This study will investigate the steady-state safety, toleration and pharmacokinetics of multiple oral dose administration of CP-945598. Results will be used to estimate the pharmacokinetic characteristics in NASH patients and underwrite the safety of this compound prior to any further studies in NASH patients.
Interventions
- DRUG Placebo
- DRUG Active treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2008-07 |
| Est. Completion | 2008-11 |
| Phase | Phase 1 |
What the finished NCT00706537 record still lists
NCT00706537 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00706537 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00706537 about?
NCT00706537 is a clinical study titled "Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH". CP-945598 is a potent and selective Cannabinoid-1 (CB1) receptor antagonist currently being developed for the treatment of obesity. CP-945598 is also being considered as a potential treatment for non-alcoholic steatohepatitis (NASH). This study will investigate the steady-state safety, toleration an...
What is the current status of trial NCT00706537?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2008-07. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00706537?
The interventions under investigation include: Placebo (DRUG), Active treatment (DRUG).
Who is sponsoring clinical trial NCT00706537?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00706537's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia